| Analysis | Metabolite Name | Measured Value | Units | CASE_CONTROL | Chemotherapy | Drug | Race | TIMEPOINT | Tamoxyfen | Taxane |
|---|---|---|---|---|---|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | 2000 | Peak area | Case | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | 3140 | Peak area | Case | N | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | 6581 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | 7561 | Peak area | Case | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | 9963 | Peak area | Control | Y | Exemestane | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | 16061 | Peak area | Case | N | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Exemestane | Black | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Exemestane | Black | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Exemestane | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Exemestane | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Letrozole | Black | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Letrozole | Black | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Letrozole | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Letrozole | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | N | Letrozole | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Exemestane | Black | 3 Month | N | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Exemestane | Black | Baseline | N | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Exemestane | White | Baseline | N | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Exemestane | Black | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Exemestane | Black | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Exemestane | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Exemestane | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Letrozole | Black | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Letrozole | Black | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Letrozole | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Letrozole | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Letrozole | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | N | Letrozole | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | TAUROCHENODEOXYCHOLATE (CAS# 516-35-8); (M+NA)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|